• Marta de la Rubia Navarro, José Rafael Ivorra Cortés, Elena Grau García, and Román IvorraJosé AndrésJAServicio de Reumatología, Hospital Universitari i Politecnic La Fe , Valencia, Spain..
• Servicio de Reumatología, Hospital Universitari i Politecnic La Fe , Valencia, Spain. Electronic address: mardena@mail.ucv.es.
• Med Clin (Barc). 2022 Oct 14; 159 (7): 344-346.

Introduction And ObjectiveBelimumab is a monoclonal antibody targeting BLyS approved for Systemic Lupus Erythematosus (SLE), with recent indication for lupus nephritis (LN). To analyze effectiveness of Belimumab in LN patients.MethodsRetrospective and cross-sectional study including SLE patients (SLICC/ACR 2012 criteria) with LN demonstrated by kidney biopsy, treated with Belimumab. A clinical history review was made and serological data, kidney function and urine sediment were collected.ResultsEight patients with LN demonstrated by kidney biopsy were included. Median age was 37.56 (7.03) years, with 15.13 (8.71) years since SLE diagnosis was made and 4.61 (2.64) years since onset of belimumab. Proteinuria was reduced to normal values in 6 patients, and renal function was stable from the beginning of treatment in all cases. There was a reduction in the anti-DNA level and normalization of complement in those cases in which it was reduced. One patient presented an increase in anti-DNA titer, with normal complement.ConclusionsIn clinical practice, belimumab can improve LN in terms of serological activity, kidney function and urine sediment.Copyright © 2022 Elsevier España, S.L.U. All rights reserved.

17 keywords...

hide…